Evaluation of the effect of guanabenz-loaded nanoparticles on chronic toxoplasmosis in mice.

Autor: Abdelhamid Elgendy WM; Medical Parasitology Department, Faculty of Medicine, Tanta University, Egypt. Electronic address: wesam.elgendy@med.tanta.edu.eg., Haggag YA; Pharmaceutical Technology Department, Faculty of Pharmacy, Tanta University, Egypt., El-Nouby KA; Medical Parasitology Department, Faculty of Medicine, Tanta University, Egypt., El-Kowrany SI; Medical Parasitology Department, Faculty of Medicine, Tanta University, Egypt., El Marhoumy SM; Medical Parasitology Department, Faculty of Medicine, Tanta University, Egypt.
Jazyk: angličtina
Zdroj: Experimental parasitology [Exp Parasitol] 2023 Mar; Vol. 246, pp. 108460. Date of Electronic Publication: 2023 Jan 13.
DOI: 10.1016/j.exppara.2023.108460
Abstrakt: Chronic toxoplasmosis which is positively correlated with many neuropsychiatric problems has no curative treatment till now; due to the resistant tissue cysts especially in the brain. In search of an effective treatment, guanabenz-loaded polyethylene glycol poly lactic-co-glycolic acid (PEG-PLGA) nanoparticles was evaluated against chronic experimental toxoplasmosis. For this purpose, each mouse was infected with 10 cysts of Toxoplasma gondii (ME 49 strain). Treated mice received either guanabenz alone (5 mg/kg/day) in subgroup IIa or guanabenz-loaded nanoparticles by full dose in subgroup IIb or guanabenz-loaded nanoparticles by the half dose (2.5 mg/kg/day) in subgroup IIc. Subgroup Ie was treated by pyrimethamine and sulfadiazine. The treatment started on day 25 post-infection for 19 successive days. Then Parasitological, histopathological, immunohistochemical, immunological and ultrastructural morphological studies were performed. The results showed that: subgroup IIb showed the highest statistically significant reduction in the neuroinflammation and brain tissue cysts (77%) with a significant higher efficacy in comparison with pyrimethamine and sulfadiazine and showed the highest level of IFN-γ, while the lowest level was in subgroup IIa. All group II mice showed similar changes of depression and compression of the wall of the cyst. This is marked in subgroup IIb with release of crescent shaped bradyzoite outside the cyst. PEG-PLGA nanoparticles had no toxic effect on the liver or the kidney of the mice. It could be concluded that guanabenz-loaded PEG-PLGA nanoparticles could be promising and safe for treatment of chronic toxoplasmosis.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: